As Pear Therapeutics’ financial situation forces the company into bankruptcy, Ben Hargreaves takes a look at whether this is just a blip on the road for digital therapeutics, or a sign of d
Following DTx West 2023 in San Mateo, California, back in February, Woebot Health’s chief clinical officer Athena Robinson spoke with pharmaphorum about the conversations had at the event,
